No drugs are currently approved to treat the underlying cause of osteoarthritis but Merck KGaA is hoping that sprifermin, which has shown promise in mid-stage trials, could be the first disease-modifying therapy for the disabling condition.
The German group's hopes are based on results from FORWARD, a five-year, Phase II study of sprifermin, a recombinant human...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?